NCT00002651 - SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer | Biotech Hunter

Enrollment

3,040

Participants

Timeline

Start Date

May 31, 1995

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Prostate Cancer

Interventions

DRUG

bicalutamide

Given orally

DRUG

goserelin acetate

Given subcutaneously

OTHER

clinical observation

Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.

Trial Locations (14)

T2N 4N2

Tom Baker Cancer Centre - Calgary, Calgary

T6G 1Z2

Cross Cancer Institute at University of Alberta, Edmonton

V5Z 1M9

University of British Columbia, Vancouver

B3H 1V7

Nova Scotia Cancer Centre, Halifax

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

N6A 4L6

London Regional Cancer Program at London Health Sciences Centre, London

K1H 8L6

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

M4N 3M5

Odette Cancer Centre at Sunnybrook, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H2L 4M1

Hopital Notre-Dame du CHUM, Montreal

H2W 1S6

McGill Cancer Centre at McGill University, Montreal

G1R 2J6

Centre Hospitalier Universitaire de Quebec, Québec

J1H 5N4

CHUS-Hopital Fleurimont, Sherbrooke

S7N 4H4

Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon